Antivirals Reduce the Formation of Key Alzheimer's Disease Molecules in Cell Cultures Acutely Infected with Herpes Simplex Virus Type 1
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) afflicts around 20 million people worldwide and so there is an urgent need for effective treatment. Our research showing that herpes simplex virus type 1 (HSV1) is a risk factor for AD for the brains of people who possess a specific genetic factor and that the virus causes accumulation of key AD proteins (β-amyloid (Aβ) and abnormally phosphorylated tau (P-tau)), suggests that anti-HSV1 antiviral agents might slow AD progression. However, currently available antiviral agents target HSV1 DNA replication and so might be successful in AD only if Aβ and P-tau accumulation depend on viral DNA replication. Therefore, we investigated firstly the stage(s) of the virus replication cycle required for Aβ and P-tau accumulation, and secondly whether antiviral agents prevent these changes using recombinant strains of HSV1 that progress only partly through the replication cycle and antiviral agents that inhibit HSV1 DNA replication. By quantitative immunocytochemistry we demonstrated that entry, fusion and uncoating of HSV1, are insufficient to induce Aβ and P-tau production. We showed also that none of the "immediate early" viral proteins is directly responsible, and that Aβ and P-tau are produced at a subsequent stage of the HSV1 replication cycle. Importantly, the anti-HSV1 antiviral agents acyclovir, penciclovir and foscarnet reduced Aβ and P-tau accumulation, as well as HSV1, with foscarnet being less effective in each case. P-tau accumulation was found to depend on HSV1 DNA replication, whereas Aβ accumulation was not. The antiviral-induced decrease in Aβ is attributable to the reduced number of new viruses, and hence the reduction in viral spread. Since antiviral agents reduce greatly Aβ and P-tau accumulation in HSV1-infected cells, they would be suitable for treating AD with great advantage unlike current AD therapies, only the virus, not the host cell, would be targeted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Honess, R. W., & Roizman, B. (1974) · Journal of Virology · doi:10.1128/jvi.14.1.8-19.1974 · Cited by 1,414 · cited 2×
“We found that staining for gC (a late protein that is dependent on DNA replication) was reduced to less than 1% of the value in the absence of antiviral, whereas staining for ICP0 (an IE protein) and UL42 (an early protein), which are independent of viral DNA replication [17], was reduced but not to the same extent (t…”
Herpes simplex virus type 1 in brain and risk of Alzheimer's disease
Itzhaki, R. F., Lin, W.-R., Shang, D., Wilcock, G. K., Faragher, B., & Jamieson, G. A. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10149-5 · Cited by 669 · cited 1×
“Also, in support of the HSV1-APOE connection are the studies showing that APOE-e4 confers a strong risk of herpes labialis, a disorder of the peripheral nervous system known to be caused (usually) by HSV1 [3,38] and also the studies showing the greater potential for HSV1 damage in infected APOE-e4-transgenic mice comp…”
Self-citationHerpes simplex virus: receptors and ligands for cell entry
Spear, P. G. (2004) · Cellular Microbiology · doi:10.1111/j.1462-5822.2004.00389.x · Cited by 581 · cited 1×
“The infectious cycle of HSV1 is a complex process, which begins with binding of the virus to heparan sulfate proteoglycan molecules on the cell surface. Subsequently the virus binds to more specific receptors which facilitate virus entry into the cell by fusion”
Preston, C. M. (1979) · Journal of Virology · doi:10.1128/jvi.29.1.275-284.1979 · Cited by 487 · cited 9×
“The presence of the ICP4 ts mutation in tsK/lacZ and in1374 was confirmed by comparison of titres at 32uC and 38.5uC.”
InfluentialSelf-citationHerpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques
Wozniak, M., Mee, A., & Itzhaki, R. (2009) · The Journal of Pathology · doi:10.1002/path.2449 · Cited by 464 · cited 4×
“Subsequently, the presence of HSV1 in the human brain was confirmed by several other groups (reviewed in [32]), using solution PCR.”
InfluentialSelf-citationEverett, R. D. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02270.x · Cited by 390 · cited 1×
“IE proteins include infected cell polypeptide (ICP) 0 and ICP4 which are transcriptional activators [18,19].”
Herpes simplex virus infection causes cellular β-amyloid accumulation and secretase upregulation
Wozniak, M. A., Itzhaki, R. F., Shipley, S. J., & Dobson, C. B. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.09.077 · Cited by 341
Self-citationJohnson, D. C., Frame, M. C., Ligas, M. W., Cross, A. M., & Stow, N. D. (1988) · Journal of Virology · doi:10.1128/jvi.62.4.1347-1354.1988 · Cited by 333 · cited 3×
“A viable HSV1 recombinant that specifies a truncated glycoprotein E (gE) (in1404), and fails to assemble a functional Fc receptor [24], did produce Ab and P-tau accumulation (Figure 1D and 2D), suggesting that the Ab and P-tau staining we observe is not an artefact due to the binding of the primary or secondary antibo…”
InfluentialLatent herpes simplex virus type 1 in normal and Alzheimer's disease brains
Jamieson, G. A., Maitland, N. J., Wilcock, G. K., Craske, J., & Itzhaki, R. F. (1991) · Journal of Medical Virology · doi:10.1002/jmv.1890330403 · Cited by 332 · cited 1×
“. Subsequent research demonstrated that the virus is present in the brain of most elderly subjects, including AD sufferers, and that it is present within the brain regions affected by AD”
Self-citationDeLuca, N. A., & Schaffer, P. A. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.8.1997 · Cited by 282
Cited by
Microbes and Alzheimer’s Disease
Itzhaki, R. F., Lathe, R., Balin, B. J., Ball, M. J., Bearer, E. L., Braak, H., Bullido, M. J., Carter, C., Clerici, M., Cosby, S. L., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160152 · Cited by 532
Self-citationSalminen, A., Kaarniranta, K., Kauppinen, A., Ojala, J., Haapasalo, A., Soininen, H., & Hiltunen, M. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.002 · Cited by 364
Harris, S. A., & Harris, E. A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142853 · Cited by 279
“Acyclovir decreased A by reducing cellular viral spreading and decreased tau phosphorylation by interfering with viral replication [166].”
BackgroundInfluentialCorroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer’s Disease
Itzhaki, R. F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00324 · Cited by 256
Self-citationA 3D human brain–like tissue model of herpes-induced Alzheimer’s disease
Cairns, D. M., Rouleau, N., Parker, R. N., Walsh, K. G., Gehrke, L., & Kaplan, D. L. (2020) · Science Advances · doi:10.1126/sciadv.aay8828 · Cited by 247
“While previous reports have suggested a potential link between HSV-1 and up-regulation of certain AD mediators (31), to date, no direct causality of AD by herpes virus in a 3D human brain model has been demonstrated.”
BackgroundAlzheimer’s Amyloid-β is an Antimicrobial Peptide: A Review of the Evidence
Gosztyla, M. L., Brothers, H. M., & Robinson, S. R. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171133 · Cited by 245
Bourgade, K., Garneau, H., Giroux, G., Le Page, A. Y., Bocti, C., Dupuis, G., Frost, E. H., & Fülöp, T. (2015) · Biogerontology · doi:10.1007/s10522-014-9538-8 · Cited by 208
Drug repositioning and repurposing for Alzheimer disease
Ballard, C., Aarsland, D., Cummings, J., O’Brien, J., Mills, R., Molinuevo, J. L., Fladby, T., Williams, G., Doherty, P., Corbett, A., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0397-4 · Cited by 201
Acyclovir in the Treatment of Herpes Viruses – A Review
Kłysik, K., Pietraszek, A., Karewicz, A., & Nowakowska, M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867325666180309105519 · Cited by 169
Time to test antibacterial therapy in Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Watling, M., & Imbimbo, B. P. (2019) · Brain · doi:10.1093/brain/awz244 · Cited by 161
Lurain, N. S., Hanson, B. A., Martinson, J., Leurgans, S. E., Landay, A. L., Bennett, D. A., & Schneider, J. A. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit210 · Cited by 159
Herpes Viruses Increase the Risk of Alzheimer’s Disease: A Meta-Analysis
Steel, A. J., & Eslick, G. D. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-140822 · Cited by 154
Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease
Linard, M., Letenneur, L., Garrigue, I., Doize, A., Dartigues, J., & Helmer, C. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12008 · Cited by 152
HSV-1 and Alzheimer’s disease: more than a hypothesis
Piacentini, R., De Chiara, G., Li Puma, D. D., Ripoli, C., Marcocci, M. E., Garaci, E., Palamara, A. T., & Grassi, C. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00097 · Cited by 130
“Wozniak et al. (2011) demonstrated that acyclovir reduced Aβ formation and Tau phosphorylation in vitro.”
BackgroundVojtechova, I., Machacek, T., Kristofikova, Z., Stuchlik, A., & Petrasek, T. (2022) · PLOS Pathogens · doi:10.1371/journal.ppat.1010929 · Cited by 92
Ball, M. J., Lukiw, W. J., Kammerman, E. M., & Hill, J. M. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.07.005 · Cited by 89
The viral hypothesis: how herpesviruses may contribute to Alzheimer’s disease
Wainberg, M., Luquez, T., Koelle, D. M., Readhead, B., Johnston, C., Darvas, M., & Funk, C. C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01138-6 · Cited by 74
“Just like in a previous cell culture study [14], the antiherpetic drug valacyclovir largely rescued these changes, with early administration (same day as HSV-1 infection) more effective than later (1 day post-infection).”
ResultWang, Z., Liu, J., Han, J., Zhang, T., Li, S., Hou, Y., Su, H., Han, F., & Zhang, C. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03166-9 · Cited by 60
“While previous reports have suggested a potential link between HSV-1 and Aβ accumulation through the use of AD mouse model and 3D human brain model [11, 13, 67, 84], the cognitive impairment and the precise modulatory mechanism behind it remain unclear.”
BackgroundMechanistic insights into the role of herpes simplex virus 1 in Alzheimer’s disease
Feng, S., Liu, Y., Zhou, Y., Shu, Z., Cheng, Z., Brenner, C., & Feng, P. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1245904 · Cited by 36
Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer’s Disease
Liu, C., & Yu, J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00297 · Cited by 27
Cytomegalovirus infection induces Alzheimer’s disease-associated alterations in tau
Mody, P. H., Marvin, K. N., Hynds, D. L., & Hanson, L. K. (2023) · Journal of NeuroVirology · doi:10.1007/s13365-022-01109-9 · Cited by 22
A reappraisal on amyloid cascade hypothesis: The role of chronic infection in Alzheimer’s disease
Phuna, Z. X., & Madhavan, P. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2045290 · Cited by 12
Metadata
- Authors
- Wozniak, M. A., Frost, A. L., Preston, C. M., & Itzhaki, R. F.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-10-07
- Volume
- 6
- Issue
- 10
- Pages
- e25152
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2092871280
- Cited by
- 172
- References
- 46
- FWCI
- 6.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.